Leerink Partnrs Has Bearish Estimate for Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Investment analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Hologic in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings of $1.02 per share for the quarter, down from their previous forecast of $1.03. The consensus estimate for Hologic's current full-year earnings is $4.09 per share. Leerink Partnrs also issued estimates for Hologic's Q3 2025 earnings at $1.08 EPS and FY2026 earnings at $4.74 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts' consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.89 earnings per share.

Several other equities research analysts have also weighed in on the stock. StockNews.com lowered shares of Hologic from a "strong-buy" rating to a "buy" rating in a report on Friday, September 27th. Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. UBS Group boosted their target price on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday. Evercore ISI raised their price target on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Hologic has a consensus rating of "Moderate Buy" and an average target price of $89.25.

Hologic Price Performance

NASDAQ:HOLX traded up $1.69 during trading hours on Wednesday, reaching $80.49. The company had a trading volume of 2,464,389 shares, compared to its average volume of 1,595,271. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a 50-day moving average of $81.05 and a two-hundred day moving average of $78.11. Hologic has a one year low of $66.93 and a one year high of $84.67. The firm has a market capitalization of $18.70 billion, a PE ratio of 26.80, a PEG ratio of 2.98 and a beta of 0.98.

Institutional Trading of Hologic

A number of institutional investors and hedge funds have recently modified their holdings of HOLX. Price T Rowe Associates Inc. MD raised its stake in Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after buying an additional 2,753,016 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider's stock worth $188,243,000 after purchasing an additional 450,190 shares during the period. Black Creek Investment Management Inc. lifted its holdings in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock valued at $172,780,000 after purchasing an additional 124,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Hologic by 4.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider's stock worth $168,666,000 after purchasing an additional 87,176 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.